News
サブ-ナビゲーション
information
現在位置:
News
Corporate Guide
Business
Investor Relations
Sustainability
Contact Us
News
2025/03/28
[Delayed] Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary
（267KB）
2025/02/13
Notice Concerning Revisions to the Financial Results Forecasts
（182KB）
2025/02/13
Consolidated Financial Results for the Nine Months Ended December 31, 2024 (Under Japanese GAAP)
（431KB）
2025/01/27
Notice Concerning Acquisition of Shares of ViSpot, Inc. (to Make It a Subsidiary)
（220KB）
2025/01/15
Notice Concerning Acquisition of Shares of Curio Bioscience, Inc. (to Make It a Subsidiary)
（245KB）
2024/11/08
Notice Concerning Differences between the Financial Forecast and the Actual Results
（209KB）
2024/11/08
Consolidated Financial Results for the Six Months Ended September 30, 2024 (Under Japanese GAAP)
（443KB）
2024/08/08
Consolidated Financial Results for the Three Months Ended June 30, 2024 (Under Japanese GAAP)
（233KB）
2024/07/31
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2024
（1,059KB）
2024/06/27
Matters Concerning Controlling Shareholders
（184KB）
2024/06/27
Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss
2024/05/28
Notice of the 22nd Annual General Meeting of Shareholders
（201KB）
2024/05/10
Notice Concerning Dividends from Surplus
（139KB）
2024/05/10
Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (Under Japanese GAAP)
（445KB）
2024/02/14
Consolidated finacial results for the nine months ended Dec 31(Under Japanese GAAP)
（368KB）
2023/11/13
Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
2023/11/09
Notice Concerning Differences between the Financial Results Forecasts and the Actual Results
（163KB）
2023/11/09
Notice Concerning Revisions to the Financial Results Forecasts
（177KB）
2023/11/09
Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under Japanese GAAP)
（427KB）
2023/10/12
Construction of the Center for Cell and Gene Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
2023/10/05
Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
2023/10/03
Takara Bio Announces Presentation of Comparability Studies for CD19 JAK/STAT CAR-T Cell Technology Transfer
2023/09/25
Takara Bio enters into a license agreement of RetroNectin® with Fondazione Telethon ETS
2023/08/30
{Delayed] Corporate Governance Report
（1,523KB）
2023/08/08
Consolidated Financial Results for the Three Months Ended June 30, 2023 (Under Japanese GAAP)
（424KB）
2023/08/08
Notice Concerning Revisions to the First Half Financial Results Forecasts
（179KB）
2023/08/01
Started using refrigerated boxes for transportation with consideration for the environment
2023/07/31
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2023
（1,551KB）
2023/06/29
Matters Concerning Controlling Shareholders
（241KB）
2023/05/29
Takara Bio Announces Poster Presentation of Data from Clinical Trial of NY-ESO-1・siTCR™ Gene Therapy at ASCO2023
2023/05/11
Notice Concerning Dividends from Surplus
（232KB）
2023/05/11
Takara Bio Group Formulated “Medium-Term Management Plan 2026”
（350KB）
2023/05/11
Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (Under Japanese GAAP)
（610KB）
2023/04/19
Indian subsidiary acquires ISO13485 certification
2023/04/03
Takara Bio Announces Initiation of Clinical Trial for Next-Generation CAR-T therapy
2023/03/02
ARTICLES OF INCORPORATION
（111KB）
2023/02/09
Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts （Dividend Increase）
（252KB）
2023/02/09
Consolidated Financial Results for the Nine Months Ended December 31, 2022（Under Japanese GAA）
（456KB）
2023/01/25
[Delayed]Takara Bio Announces Transfer of SAKIGAKE and Orphan Designations for NY-ESO-1/siTCR Gene Therapy Product
（229KB）
2022/11/10
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for NY-ESO-1・siTCR™ gene therapy candidate
2022/11/10
Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (Dividend Increase)
（186KB）
2022/11/10
Consolidated Financial Results for the Six Months Ended September 30, 2022 (Under Japanese GAAP)
（404KB）
2022/10/25
Notice Concerning Revisions to the First Half Financial Results Forecasts
（244KB）
2022/09/16
[Correction] Annual Securities Report for the Fiscal Year Ended March 31, 2022
（212KB）
2022/09/08
Launched CDMO service for gene therapy products using siTCR® technology or JAK/STAT technology
2022/09/06
Annual Report 2022
（8,041KB）
2022/08/29
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2022
（1,191KB）
2022/08/04
Consolidated Financial Results for the Three Months Ended June 30, 2022 (Under Japanese GAAP)
（394KB）
2022/07/22
Launched a CDMO service using CereAAV™, a brain-tropic AAV vector for gene therapy
2022/07/06
[Delayed] Corporate Governance Report
（770KB）
2022/06/13
Notice of the 20th Annual General Meeting of Shareholders
（208KB）
2022/06/01
Takara Bio to Present Clinical Data from Investigator-Initiated Trial in Canada of NY-ESO-1・siTCR™ Gene Therapy at ASCO2022 【Poster Posted】
2022/05/12
Notice of Dividends of Surplus
（135KB）
2022/05/12
Consolidated Financial Statements for the Year Ended March 31, 2022 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED]
（350KB）
2022/04/25
Takara Bio Announces a Novel Brain-Tropic AAV Vector "CereAAV™" for Gene Therapy
2022/02/10
Notice Concerning Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（250KB）
2022/02/10
Consolidated Financial Statements for the Third Quarter Ended December 31, 2021 FY2022 (April 1, 2021-March 31, 2022) [UNAUDITED]
（771KB）
2022/01/24
Notice Concerning Recording of Extraordinary Gains and Losses Related to Subsidization
（248KB）
2022/01/20
[Delayed] Corporate Governance Report
（768KB）
2021/12/02
Implementation of the Center for Gene and Cell Processing to Respond to Diverse Modalities and Develop Supply Chains
2021/11/09
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for Oncolytic virus HF10 and CD19-targeted CAR Gene Therapies
2021/11/09
Notice of Revisions of Financial Forecast and Dividend Forecast (Dividend Increase)
（138KB）
2021/11/09
Consolidated Financial Statements for the Second Quarter Ended September 30, 2021 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED]
（339KB）
2021/10/21
Notice of Revision of Financial Forecast
（241KB）
2021/09/21
Notice of Resolution of the Board of Directors on Selection of “Prime Market” Listing on the Tokyo Stock Exchange under the New Market Segments
（224KB）
2021/08/06
[Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED]
（596KB）
2021/08/06
[Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED]
（154KB）
2021/08/03
Notice of Revision of Financial Forecast and Dividend Forecast (Dividend Increase)
（139KB）
2021/08/03
Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 － June 30, 2021) 〔UNAUDITED〕
（596KB）
2021/06/21
Takara Bio enters into a license and supply agreement of RetroNectin® with BioNTech Cell & Gene Therapies GmbH
2021/05/13
Consolidated Financial Statements for the Year Ended March 31, 2021 FY2021 (April 1, 2020 - March 31, 2021) [UNAUDITED]
（695KB）
2021/02/10
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（287KB）
2021/02/10
Consolidated Financial Statements for the Third Quarter Ended December 31, 2020 FY2021 (April 1, 2020 - March 31, 2021)［UNAUDITED］
（915KB）
2021/02/01
Takara Bio Acquires ISO13485 Certification
2021/01/05
Corporate Governance Report
（681KB）
2020/11/25
We have posted "Financial Results Presentation".
（1,020KB）
2020/11/10
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（217KB）
2020/11/10
Consolidated Financial Statements for the Second Quarter Ended September 30, 2020 FY2021 (April 1, 2020 - September 30, 2020) [UNAUDITED]
（681KB）
2020/11/06
We have issued "Annual Report 2020".
（1,023KB）
2020/10/21
【Delayed】Announcement on Revision of Financial Forecast
（225KB）
2020/08/05
【Delayed】Announcement on revision of financial forecast
（369KB）
2020/08/05
【Delayed】Consolidated Financial Statements for the First Quarter Ended June 30, 2020 FY2021 (April 1, 2020 - June 30, 2020)
（780KB）
2020/08/04
Summary of Financial Results for the first quarter 2021
（366KB）
2020/08/04
Takara Bio terminates the license agreement relating to Oncolytic Virus C-REV with Tasly Biopharmaceuticals, China
（285KB）
2020/06/26
We have posted "Financial Results Presentation".
（670KB）
2020/06/24
Clinical program for NY-ESO-1・siTCR(TM) gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
2020/06/08
Takara Bio Group’s Formulation of Long-Term Management Plan FY2026 and Medium-Term Management Plan FY2023
（994KB）
2020/05/28
Notice of the 18th Annual General Meeting of Shareholders
（163KB）
2020/05/19
【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2020 FY2020 (April 1, 2019 -March 31, 2020)[UNAUDITED]
（710KB）
2020/05/14
Summary of Financial Results 2020
（430KB）
2020/05/13
【Delayed】Takara Bio has entered into a license agreement relating to C-REV with Tasly Biopharmaceuticals, China
（227KB）
2020/03/06
Takara Bio to Support Development of Novel Coronavirus VaccineUndertaken by Osaka University Group
2020/02/13
Consolidated Financial Statements for the Third Quarter Ended December 31, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（625KB）
2020/01/21
Takara Bio Launches a New Facility for the Research and Manufacturing of Regenerative Medicine Products
2020/01/16
Takara Bio and Tmunity Enter into License Agreement to Advance siRNA Technology to Improve T cell Therapies
2019/11/21
We have posted "financial results presentation".
（551KB）
2019/11/12
Consolidated Financial Statements for the Second Quarter Ended September 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（626KB）
2019/09/27
Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV
（247KB）
2019/09/27
We have issued "Annual Report 2019".
（1,044KB）
2019/09/24
Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1・siTCR Gene Therapy at ESMO 2019
2019/08/14
Corporate Governance Report
（514KB）
2019/08/06
Consolidated Financial Statements for the First Quarter Ended June 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（583KB）
2019/05/30
Notice of the 17th Annual General Meeting of Shareholders
（148KB）
2019/05/22
We have posted "Financial Results Presentation".
（820KB）
2019/05/16
Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1・siTCR Gene Therapy at ASCO 2019
2019/05/14
Consolidated Financial Statements for the Year Ended March 31, 2019 FY2019 (April 1, 2018 - March 31, 2019)［UNAUDITED］
（795KB）
2019/05/14
Summary of Financial Results 2019
（399KB）
2019/05/07
A wholly-owned subsidiary, Takara Biotechnology (Dalian) Co., Ltd. Acquires ISO:13485 certification
2019/04/26
Takara Bio to Acquire an Exclusive License to Use Patent Technology Relating to New Generation CAR Gene Therapy
2019/04/26
Joint Research on New Development of CAR Gene Therapy with Mie University
2019/04/24
Joint Research on Novel Approach to Cancer Immune and Gene Therapy with Department of Immunotherapeutics, The University of Tokyo Hospital
2019/04/03
Takara Bio Submits Drug Master File to the U.S. FDA for RetroNectin® GMP grade (Solution Type)
2019/03/29
Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan
（194KB）
2019/02/15
Designation Description Change of NY-ESO-1・siTCR gene therapy product under “SAKIGAKE Designation System”
2019/02/08
Corporate Governance Report
（496KB）
2019/02/06
【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED]
（932KB）
2019/01/30
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（259KB）
2019/01/30
Summary of Financial Results for the third quarter 2019
（488KB）
2019/01/16
Takara to Present Oncolytic Virus C-REV Preliminary Data from the Phase I trial Targeting Unresectable Pancreatic Cancer at ASCO-GI 2019 Congress
2018/12/17
Notice Regarding Transfer of Mushroom Business
（316KB）
2018/11/14
We have posted "Financial Results Presentation".
（684KB）
2018/11/06
Consolidated Financial Statements for the Second Quarter Ended September 30, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED]
（728KB）
2018/11/06
Summary of Financial Results for the second quarter 2019
（390KB）
2018/10/22
Announcement of Participation in AMED Project “Research and development of core technologies for gene and cell therapy”
2018/10/19
Oncolytic Virus C-REV Data Presentation of Phase II trial Targeting Unresectable or Metastatic Melanoma in Japan at ESMO 2018 Congress
2018/10/15
CAP-LAP Certification of Clinical Testing Laboratory for Takara Bio's Cancer Genetic Testing Business conducted in Osaka University Hospital
2018/09/28
【Delayed】Notice Regarding Business Reorganization by Simplified Absorption-type Company Split
（241KB）
2018/09/03
Out-licensing agreement for commercial use of RetroNectin® into Daiichi Sankyo
2018/09/03
We have issued "Annual Report 2018".
（2,549KB）
2018/08/22
Takara Bio entered into a licensing agreement relating to Oncolytic Virus "Canerpaturev" with Dong-A ST, South Korea
（195KB）
2018/07/31
Consolidated Financial Statements for the First Quarter Ended June 30, 2018 FY2019(April 1, 2018-March 31, 2019)[UNAUDITED]
（182KB）
2018/07/31
Summary of Financial Results for the first quarter 2019
（109KB）
2018/07/26
Takara Bio granted manufacturing license from the Swedish Medical Product Agency for clinical-grade human embryonic stem cell line derivation and banking
2018/06/08
【Delayed】Announcement on revision of Takara Bio Medium-Term Management Plan FY2020
（533KB）
2018/06/08
【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2018 FY2018 (April 1, 2017 - March 31, 2018)[UNAUDITED]
（780KB）
2018/05/31
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2018/04/09
Takara Bio entered into an agreement for co-development/exclusive sales of NY-ESO-1・siTCR and CD19 CAR gene therapy with Otsuka
2018/04/06
Announcement on product designation of NY-ESO-1・siTCR gene therapy product for synoviral sarcoma under “SAKIGAKE Designation System” by the Ministry of Health, Labour and Welfare
2018/02/19
Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products
2018/02/13
【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2017 FY2017 (April 1, 2017 - March 31, 2018) [UNAUDITED]
（832KB）
2018/01/30
Summary of Financial Results for the third quarter 2018
（96KB）
2018/01/19
First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR gene therapy against synovial sarcoma in Japan
2017/12/21
Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab
2017/11/28
Consolidated Financial Statements for the Second Quarter Ended September 30, 2017
（1,571KB）
2017/11/06
Revision of Consolidated Business Results Forecast ｆor the First Half of the Fiscal Year Ending March 31, 2018
（221KB）
2017/11/06
Exclusive Global License for New Method of iPS Cell Production Obtained
2017/09/27
First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan
2017/08/21
Consolidated Financial Statement for the First Quarter Ended June 30, 2017
（891KB）
2017/07/27
Summary of Consolidated Financial Statement for the First Quarter Ended June 30, 2017
（367KB）
2017/06/01
Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan
2017/05/29
First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan
2017/05/23
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2017/05/09
Consolidated Financial Statement for the year ended March 31, 2017, released on May 9, 2017
（791KB）
2017/05/09
Formulation of Takara Bio Medium-Term Management Plan FY2020
（243KB）
2017/03/01
Takara Bio USA Holdings, Inc. completes acquisition of WaferGen Bio-systems, Inc.
2017/01/30
Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan
2017/01/24
Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan
2017/01/18
Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc.
2017/01/11
Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan
2016/12/15
Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus
2016/12/15
Takara Bio USA Holdings, Inc. and Rubicon Genomics Announce Merger Agreement
2016/06/21
Takara Bio enters into a license and supply agreement of RetroNectin® with Kite Pharma
2016/05/19
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2016/03/22
Takara Bio grants Cellectis SA a commercial license to use RetroNectin®
2016/02/02
Center for Gene and Cell Processing wins 2016 Facility of the Year Awards
2016/01/27
Establishment of a cell processing facility in “Life Innovation Center (provisional name)” in Tono-machi, Kawasaki city, as the implementation/ industrialization hub for cell therapy and regenerative medicine
2016/01/25
Release of GMP grade PCR enzyme for genetic diagnosis
2016/01/14
Notice of change in the Company Name, consolidated subsidiary, United States-based Clontech Laboratories, Inc.
2015/10/27
HF10 Phase II clinical trial data presented at AACR-NCI-EORTC international conference
2015/09/29
Licensing agreement for manufacturing iPS cells using Sendai virus vector
2015/09/14
HF10 Phase I clinical trial data presented at European Society for Medical Oncology 2015 Congress
2015/08/10
Completion of a new facility and relocation of head office
2015/08/04
The 1st HF10 therapy in Japan was started against solid cancers
2015/07/24
Regenerative medicine based on dental pulp cells
2015/07/23
Takara Bio launches High-performance real-time PCR system
2015/06/17
Acquisition of ISO 9001 certification aiming at improvement in quality of products and services in regenerative medicine fields
2015/06/10
Patent regarding siTCR vector a core technique of gene therapy is granted in the U.S.
2015/06/01
Takara Bio launches culture medium specifically designed for iPS cells for research-use in regenerative medicine field
2015/05/19
Takara Bio is selected for ”Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine”
2015/05/13
Accreditation of the foreign cell processor: Takara Bio can start specific processed cell manufacturing and provide contracted cell processing service to medical institutions
2014/11/10
Acquisition of assets for stem cell-related research products from StemCells Inc.
2014/11/04
License Agreement with iPS Academia Japan Inc.
2014/10/30
Takara Bio receives NEDO Grant to develop mass production of cardiomyocytes derived from human iPS cells
2014/10/27
License agreement for genome editing with Broad Institute
2014/10/01
Marketing of Cellartis™ products started
2014/07/29
Acquisition of stem cell business firm (former Cellartis AB) from Cellectis SA
2014/06/24
Agreement with iHeart Japan Corporation
2014/05/30
Takara Bio reseives NEDO Grant to develop cell manufacturing and processing systems for industrialization of regenerative medicine
2014/05/08
Takara Bio Group’s Mid-term Management Plan
2014/05/01
Takara Bio submitted an Investigational New Drug application for a Phase II clinical trial of HF10 anti-cancer therapy to the Food and Drug Administration
2014/03/13
Clinical research protocol of gene therapy targeting B cell non-Hodgkin Lymphoma was approved by Japanese Ministry
2014/03/03
Takara Bio obtains a governmental grant for commercialization of its TCR gene therapy projects
2014/02/10
Submission of the application for Investigator-initiated Phase I clinical trials of MAGE-A4 TCR gene therapy as Japan’s first genetic immunotherapy for cancer
2014/01/09
Takara Bio releases Mouse Feeder Cell Quantification Kit for quality control of human stem cells
Back to List
PAGETOP
PAGETOP
CLOSE
MENU
サイト内検索
menu
JA
EN
contact
gnavi-box
